These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28298546)

  • 1.
    Lee H; Shields AF; Siegel BA; Miller KD; Krop I; Ma CX; LoRusso PM; Munster PN; Campbell K; Gaddy DF; Leonard SC; Geretti E; Blocker SJ; Kirpotin DB; Moyo V; Wickham TJ; Hendriks BS
    Clin Cancer Res; 2017 Aug; 23(15):4190-4202. PubMed ID: 28298546
    [No Abstract]   [Full Text] [Related]  

  • 2. A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.
    Lee H; Zheng J; Gaddy D; Orcutt KD; Leonard S; Geretti E; Hesterman J; Harwell C; Hoppin J; Jaffray DA; Wickham T; Hendriks BS; Kirpotin D
    Nanomedicine; 2015 Jan; 11(1):155-65. PubMed ID: 25200610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Companion Diagnostic
    Lee H; Gaddy D; Ventura M; Bernards N; de Souza R; Kirpotin D; Wickham T; Fitzgerald J; Zheng J; Hendriks BS
    Theranostics; 2018; 8(9):2300-2312. PubMed ID: 29721081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
    Geretti E; Leonard SC; Dumont N; Lee H; Zheng J; De Souza R; Gaddy DF; Espelin CW; Jaffray DA; Moyo V; Nielsen UB; Wickham TJ; Hendriks BS
    Mol Cancer Ther; 2015 Sep; 14(9):2060-71. PubMed ID: 26162690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
    Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
    Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-
    Du Y; Liang X; Li Y; Sun T; Jin Z; Xue H; Tian J
    Mol Pharm; 2017 Nov; 14(11):3978-3986. PubMed ID: 29016143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
    Pircher M; Mlineritsch B; Fridrik MA; Dittrich C; Lang A; Petru E; Weltermann A; Thaler J; Hufnagl C; Gampenrieder SP; Rinnerthaler G; Ressler S; Ulmer H; Greil R
    Anticancer Res; 2015 Jan; 35(1):517-21. PubMed ID: 25550597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
    Espelin CW; Leonard SC; Geretti E; Wickham TJ; Hendriks BS
    Cancer Res; 2016 Mar; 76(6):1517-27. PubMed ID: 26759238
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles.
    England CG; Im HJ; Feng L; Chen F; Graves SA; Hernandez R; Orbay H; Xu C; Cho SY; Nickles RJ; Liu Z; Lee DS; Cai W
    Biomaterials; 2016 Sep; 100():101-9. PubMed ID: 27254470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
    Tamura K; Kurihara H; Yonemori K; Tsuda H; Suzuki J; Kono Y; Honda N; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Hasegawa K; Kanayama Y; Nozaki S; Kinoshita T; Wada Y; Tazawa S; Takahashi K; Watanabe Y; Fujiwara Y
    J Nucl Med; 2013 Nov; 54(11):1869-75. PubMed ID: 24029656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics.
    Børresen B; Henriksen JR; Clergeaud G; Jørgensen JS; Melander F; Elema DR; Szebeni J; Engelholm SA; Kristensen AT; Kjær A; Andresen TL; Hansen AE
    ACS Nano; 2018 Nov; 12(11):11386-11398. PubMed ID: 30372038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes.
    Hansen AE; Petersen AL; Henriksen JR; Boerresen B; Rasmussen P; Elema DR; af Rosenschöld PM; Kristensen AT; Kjær A; Andresen TL
    ACS Nano; 2015 Jul; 9(7):6985-95. PubMed ID: 26022907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.